Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2020 | Significance of oral hypomethylating agents

Amer Zeidan • 1 Jun 2020
ASCO 2020
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Azacitidine Decitabine
QUAZAR AML-001

Amer Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, New Haven, CT, highlights the importance of the development of oral hypomethylating agents to improve patient compliance and outcomes. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Amer Zeidan

Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS
1:10
Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS
Amer Zeidan • 5 Dec 2025
Oral decitabine plus venetoclax for older unfit patients with AML: results of a Phase II study
2:02
Oral decitabine plus venetoclax for older unfit patients with AML: results of a Phase II study
Amer Zeidan • 5 Dec 2025
Luspatercept initiated at the maximum-approved dose in transfusion-dependent LR-MDS: MAXILUS trial
1:11
Luspatercept initiated at the maximum-approved dose in transfusion-dependent LR-MDS: MAXILUS trial
Amer Zeidan • 5 Dec 2025
Ziftomenib with azacitidine and venetoclax in NPM1-mutated AML: the KOMET-007 trial
1:57
Ziftomenib with azacitidine and venetoclax in NPM1-mutated AML: the KOMET-007 trial
Amer Zeidan • 5 Dec 2025

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Amer Zeidan • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Amer Zeidan • 6 Dec 2025
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
3:16
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
Amer Zeidan • 6 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Amer Zeidan • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals